分子靶向治疗：闸门已经打开了吗？ - Suppr

Suppr

超能文献

Molecularly targeted therapy: have the floodgates opened?

作者信息

Druker Brian J

机构信息

Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA.

出版信息

Oncologist. 2004;9(4):357-60. doi: 10.1634/theoncologist.9-4-357.

DOI:10.1634/theoncologist.9-4-357

PMID:15266089

Abstract

摘要

相似文献

Molecularly targeted therapy: have the floodgates opened?

Oncologist. 2004;9(4):357-60. doi: 10.1634/theoncologist.9-4-357.

Another possible mechanism of resistance to STI571.

Blood. 2000 Dec 1;96(12):4003-5.

Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.

J Natl Cancer Inst. 2000 Oct 18;92(20):1626-7. doi: 10.1093/jnci/92.20.1626.

Cancer stem cells: are we missing the target?

J Natl Cancer Inst. 2004 Apr 21;96(8):583-5. doi: 10.1093/jnci/djh095.

Imatinib mesylate.

Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.

Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.

J Assoc Physicians India. 2007 Feb;55:99-100.

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

J Cancer Res Clin Oncol. 2004 Feb;130(2):59-72. doi: 10.1007/s00432-003-0502-2. Epub 2003 Nov 7.

STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?

Tumori. 2001 Nov-Dec;87(6):S10-2.

A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.

J Natl Cancer Inst. 1999 Jan 20;91(2):102-3. doi: 10.1093/jnci/91.2.102.

Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.

J Natl Cancer Inst. 2003 Jul 16;95(14):1087-8; author reply 1088-9. doi: 10.1093/jnci/95.14.1087-a.

引用本文的文献

Advances in development of new tools for the study of phosphohistidine.

Lab Invest. 2018 Mar;98(3):291-303. doi: 10.1038/labinvest.2017.126. Epub 2017 Dec 4.

Inference of dynamic biological networks based on responses to drug perturbations.

EURASIP J Bioinform Syst Biol. 2014 Sep 25;2014:14. doi: 10.1186/s13637-014-0014-1. eCollection 2014 Dec.

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Eur J Cancer. 2014 Mar;50(5):981-6. doi: 10.1016/j.ejca.2013.11.037. Epub 2014 Jan 2.

A new approach for prediction of tumor sensitivity to targeted drugs based on functional data.

BMC Bioinformatics. 2013 Jul 29;14:239. doi: 10.1186/1471-2105-14-239.

Chasing phosphohistidine, an elusive sibling in the phosphoamino acid family.

ACS Chem Biol. 2012 Jan 20;7(1):44-51. doi: 10.1021/cb200445w. Epub 2011 Dec 9.

Development of stable phosphohistidine analogues.

J Am Chem Soc. 2010 Oct 20;132(41):14327-9. doi: 10.1021/ja104393t.

Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

J Immunol. 2010 Jun 1;184(11):6529-36. doi: 10.4049/jimmunol.0903562. Epub 2010 Apr 26.

c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.

Clin Cancer Res. 2010 Jan 1;16(1):184-94. doi: 10.1158/1078-0432.CCR-09-1180. Epub 2009 Dec 22.

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

J Clin Invest. 2007 Dec;117(12):4044-54. doi: 10.1172/JCI32373.

Kinase packing defects as drug targets.

Drug Discov Today. 2007 Nov;12(21-22):917-23. doi: 10.1016/j.drudis.2007.09.009. Epub 2007 Oct 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Molecularly targeted therapy: have the floodgates opened?

Oncologist. 2004;9(4):357-60. doi: 10.1634/theoncologist.9-4-357.

Another possible mechanism of resistance to STI571.

Blood. 2000 Dec 1;96(12):4003-5.

Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.

J Natl Cancer Inst. 2000 Oct 18;92(20):1626-7. doi: 10.1093/jnci/92.20.1626.

Cancer stem cells: are we missing the target?

J Natl Cancer Inst. 2004 Apr 21;96(8):583-5. doi: 10.1093/jnci/djh095.

Imatinib mesylate.

Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.

Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.

J Assoc Physicians India. 2007 Feb;55:99-100.

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

J Cancer Res Clin Oncol. 2004 Feb;130(2):59-72. doi: 10.1007/s00432-003-0502-2. Epub 2003 Nov 7.

STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?

Tumori. 2001 Nov-Dec;87(6):S10-2.

A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.

J Natl Cancer Inst. 1999 Jan 20;91(2):102-3. doi: 10.1093/jnci/91.2.102.

Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.

J Natl Cancer Inst. 2003 Jul 16;95(14):1087-8; author reply 1088-9. doi: 10.1093/jnci/95.14.1087-a.

引用本文的文献

Advances in development of new tools for the study of phosphohistidine.

Lab Invest. 2018 Mar;98(3):291-303. doi: 10.1038/labinvest.2017.126. Epub 2017 Dec 4.

Inference of dynamic biological networks based on responses to drug perturbations.

EURASIP J Bioinform Syst Biol. 2014 Sep 25;2014:14. doi: 10.1186/s13637-014-0014-1. eCollection 2014 Dec.

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Eur J Cancer. 2014 Mar;50(5):981-6. doi: 10.1016/j.ejca.2013.11.037. Epub 2014 Jan 2.

A new approach for prediction of tumor sensitivity to targeted drugs based on functional data.

BMC Bioinformatics. 2013 Jul 29;14:239. doi: 10.1186/1471-2105-14-239.

Chasing phosphohistidine, an elusive sibling in the phosphoamino acid family.

ACS Chem Biol. 2012 Jan 20;7(1):44-51. doi: 10.1021/cb200445w. Epub 2011 Dec 9.

Development of stable phosphohistidine analogues.

J Am Chem Soc. 2010 Oct 20;132(41):14327-9. doi: 10.1021/ja104393t.

Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

J Immunol. 2010 Jun 1;184(11):6529-36. doi: 10.4049/jimmunol.0903562. Epub 2010 Apr 26.

c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.

Clin Cancer Res. 2010 Jan 1;16(1):184-94. doi: 10.1158/1078-0432.CCR-09-1180. Epub 2009 Dec 22.

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

J Clin Invest. 2007 Dec;117(12):4044-54. doi: 10.1172/JCI32373.

Kinase packing defects as drug targets.

Drug Discov Today. 2007 Nov;12(21-22):917-23. doi: 10.1016/j.drudis.2007.09.009. Epub 2007 Oct 30.